Clinical trials: Chronic Metabolic Disorder
Cardiometabolic Syndrome
Establishing Clinical Utility Evidence for Chronic Disease Management Testing
This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care…
- Trial name
- NCT05192590
- Testing
- Educational Materials and Chronic Disease Management Test (CDMT)
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Qure Healthcare, LLC
Chronic Kidney Disease, End Stage Renal Disease
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification
- Trial name
- NCT00379899
- Testing
- cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Hungary Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES)
- Trial name
- NCT01892917
- Where
- 13 sites in Hungary
- Volunteers
- 2,000 people
- Sponsor
- Biotronik Hungária Kft.
Diabetes Mellitus, Type 2
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
to determine safety, efficacy and tolerability of BI 1356 versus placebo
- Trial name
- NCT00800683
- Testing
- BI 1356
- Where
- 53 sites in United States, Australia and 4 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Hunter Syndrome, Mucopolysaccharidosis II
Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy
The objective of this study is to determine the safety of once weekly dosing of idursulfase 0.5 mg/kg administered by intravenous (IV) infusion for male Hunter syndrome patients ≤ 5 years old.
- Conditions
- Hunter Syndrome, Mucopolysaccharidosis II, MPS II
- Trial name
- NCT00607386
- Testing
- Idursulfase
- Where
- 3 sites in Brazil, Poland and 1 more
- Volunteers
- 28 people
- Sponsor
- Shire
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Truway Diagnostic Tools in Primary Care
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings.
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute
- Trial name
- TruDxPC (NCT07209527)
- Testing
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Anemia, Iron-Deficiency
A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients
The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with…
- Trial name
- NCT02570854
- Testing
- CSJ137
- Where
- 13 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure, Type 2 Diabetes
Prognostic Impact of Diabetes and Weight Variability in Telemonitored Heart Failure
This observational cohort study evaluates the prognostic impact of diabetes, comorbidity burden, and short-term weight variability among adults with chronic heart failure enrolled in a nationwide remote patient monitoring program…
- Conditions
- Chronic Heart Failure, Type 2 Diabetes, Diabetes (DM)
- Trial name
- DM-HF-Tele (NCT07561866)
- Testing
- Diabetes Status, Comorbidity Burden, Weight variability
- Where
- France
- Volunteers
- 16,556 people
- Sponsor
- Satelia
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Canada Satellite Registry
For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedural success.
- Trial name
- NCT01880242
- Where
- 2 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Biotronik Canada Inc
Chronic Myeloid Leukemia
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
This study will evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam (as a sensitive CYP3A probe) in CML patients.
- Trial name
- NCT01223898
- Testing
- Tasigna
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Belgium Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01831336
- Where
- 8 sites in Belgium
- Volunteers
- 332 people
- Sponsor
- Biotronik Belgium NV
Hypophosphatasia
Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
The study will evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 2 different doses (approved dose and lower dose) of asfotase alfa in adult participants with pediatric-onset hypophosphatasia (HPP).
- Trial name
- REBUILD (NCT04189315)
- Testing
- asfotase alfa
- Sponsor
- Alexion Pharmaceuticals, Inc.
Obesity, Overweight
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with…
- Trial name
- NCT06143956
- Testing
- LY3305677, LY3841136, Tirzepatide
- Where
- 57 sites in United States, Argentina
- Volunteers
- 1,481 people
- Sponsor
- Eli Lilly and Company
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
H1N1 Influenza Virus, Chronic Pulmonary Disease
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Conditions
- H1N1 Influenza Virus, Chronic Pulmonary Disease, Chronic Heart Disease, Diabetes Mellitus
- Trial name
- NCT01032395
- Testing
- Focetria®, Fluad®, Begrivac®
- Where
- 2 sites in Brazil
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Iron Deficiency Anemia
Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
The objective of this study is to assess the safety and tolerability of Venofer in patients with chronic kidney disease who cannot tolerate Ferumoxytol (Feraheme) or intravenous iron containing a dextran (INFed or Dexferrum).
- Trial name
- ASSURED (NCT01151592)
- Testing
- Iron Sucrose
- Where
- United States
- Sponsor
- American Regent, Inc.
Pre-diabetes, Insulin Sensitivity
Understanding Dose Related Effects of Strawberry
The proposed research is designed to extend previous research findings building on the knowledge of strawberries as fruits that support a healthy immune and vascular system.
- Conditions
- Pre-diabetes, Insulin Sensitivity, Insulin Resistance, Inflammation
- Trial name
- STRW (NCT06173765)
- Testing
- freeze-dried whole strawberry powder 36 g powder, freeze-dried whole strawberry powder 12 g, freeze-dried control powder 0 g strawberry
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc